AIDS TREATMENT NEWS No. 117 - December 21, 1990
Denny Smith
The following selective index is maintained and used in our office to answer inquiries. It does not include every possible reference from our back issues, only those which still seem substantial or relevant. For information concerning topics not addressed by AIDS TREATMENT NEWS, we recommend the following other publications to our readers:
* AmFAR's AIDS/HIV Experimental Treatment Directory: 212/719-0033.
* Bulletin of Experimental Treatments for AIDS (BETA): 863-2437 in San Francisco, 800/327-9893 rest of U. S.
* Directory of Antiviral and Immunomodulatory Therapies for AIDS (DAITA): 205/991-6920.
* PI Perspectives and Project Inform fact sheets: 558-9051 in San Francisco, 800/334-7422 rest of California, 800/822-7422 rest of U. S. ; 415/558-9051 from other countries.
* Treatment and Data Digest of ACT UP/New York: 155 E. 31st Street, Suite #20-L, New York, NY 10016.
* Treatment Issues, published by Gay Men's Health Crisis: 212/337-1950.
Article Issue Numbers
ACT UP 82, 101, 103, 106, 108, 111, 112,117 acyclovir (Zovirax) 83, 94, 108, 115 aerosol pentamidine 88, 90, 114 AL 721 (egg lecithin/lipids) 42, 43, 44, 55 alpha interferon 75, 87, 101 amikacin 109 amphotericin 41, 58 Ampligen 34, 67 Antabuse (disulfiram) 29, 70 anemia 82 anti-idiotype antibody therapy 93, 110 Asacol 109 ascorbate 111 aspirin 109 AzdU (azidouridine, CS-87) 72 azithromycin 75, 79, 108, 109, 111, 113 AZT (zidovudine, Retrovir) 83, 86, 90, 95, 100, 107, 110, 113, 115
Bactrim (co-trimoxazole, TMP-SMX) 108, 114 benefits 74, 76, 105 BHT 10, 71 BI-RG-587 117 bleomycin 73 blue-green algae (sulfolipids) 87, 99 buyers' clubs 117
candidiasis (thrush) 37, 96 castanospermine 35 CDA (chlorodeoxyadenosine) 93, 110 CD4 (recombinant soluble) 62 chemotherapy 73, 75, 93, 110 children/infants 90, 114, 117 Chinese medicine 61, 68, 75, 93, 107 Chronic Fatigue Syndrome (CFIDS) 93 cimetidine (Tagamet) 80 clarithromycin 109, 113 clindamycin 79, 104, 108, 111 clofazimine (Lamprene) 79, 109 CMV 71, 76, 83, 89, 94, 96, 108, 110 coccidioidomycosis (valley fever) 41, 96 cofactors 83, 108 coenzyme Q (ubiquinone) 26 combination therapies 107, 115 community research 65, 66, 83, 85 compound Q (GLQ 223, trichosanthin) 82, 88, 99, 104 computerized information 83, 102, 114, 116 CPFs 108 cryptococcal meningitis 41, 58, 96, 99 cryptosporidiosis 49, 58, 75, 80, 95, 107, 111, 113 cytarabine (ARA-C) 79, 93
d4T 72 dapsone 79, 114 ddC 89, 103, 104, 112, 113, 115 ddI 83, 88, 99, 103, 110, 112 dementia 97, 101 dextran sulfate 50, 76, 89 dexamethasone (Decadron) 79, 88, 93 DHEA (EL 10) 48, 49, 84 diagnosis accuracy 100, 111 diclazuril (Clinicox) 80, 95, 107, 111 DNCB 14, 116 doctor/patient relations 100, 111 doxorubicin (Adriamycin) 73 doxycycline 95, 104, 108 D-penicillamine 35 DTC (Imuthiol) 29, 70, 114
eflornithine (DFMO) 94, 95 encephalitis 79, 97 epidemiology 97, 99 EPO (erythropoietin) 82 Epstein-Barr Virus (EBV) 93, 94 etoposide 73
Fansidar 42, 108, 114 FIAC 94 566C80 108, 109, 114 FLT (fluorodeoxythymidine) 72 fluconazole (Diflucan) 41, 58, 80, 96, 103 Foscarnet 71, 83, 94, 108, 110 funding/lobbying 97, 99, 111 fusidic acid (Fusidin) 42, 79
gamma interferon 108 ganciclovir (DHPG, Cytovene) 71, 89, 94, 96, 108 gentamicin 109 germanium 90 glycyrrhizin 17, 103, 115 GM-CSF 87, 93, 94, 105, 108, 110
health care politics 99, 102, 103, 111, 112 hemophilia 89, 102, 103 heparin 100 herpes/shingles 80, 83, 94, 100, 115 histoplasmosis 41, 96 HOE/BAY 964 59 HPMPC 76, 96 Humatin (paromomycin) 107, 111 hybridons (anti-sense) 58 hydrogen peroxide 49 hypericin 80, 86, 88, 91, 96 hyperimmune milk (colostrum) 49, 95, 107 hyperthermia 104
ibuprofen (Advil) 109 immigration 89, 98, 114 Imuthiol (DTC) 29, 70, 114 indomethacin 109 infection prevention 79, 90 insurance 74, 76 interferons 75, 87, 101, 114 Iscador (mistletoe compound) 92 isoprinosine 106 ITP 48 itraconazole (Sporanox) 80, 96
Kaposi's sarcoma (KS) 73, 75, 87, 99, 100 Kemron 97, 101, 114
laser treatments 75, 96 lentinan 19, 73 leucovorin 49, 52, 79 liposomes 109 L671,329 114 lymphoma 93, 110
MAI/MAC 79, 109, 113 mebeciclol 95 Megace (megestrol acetate) 76, 77 MEK 99 melanins 107 mitoxantrone 93 mycoplasma 95, 108
NAC 88, 92, 93 naltrexone 16, 52 neopterin 86, 100 neutropenia 94, 100 neuropsychiatric effects 97, 101 nonsteroidal anti-inflammatory drugs 109 nutrition 73
ozone 80
parallel track 82, 84, 85, 104 paromomycin (Humatin) 107, 111 passive immunotherapy 67, 92 patient/doctor relations 100, 111 PCR 62 pediatric AIDS 90, 117 people of color 86, 99 Peptide T 84 Persantine (dipyridamole) 79 pharmacies 64, 86 physician interviews 47, 54, 56, 62, 100, 106 PML 79, 88, 100, 115 Pneumocystis pneumonia (PCP) 58, 83, 90, 106, 114, 115 polio vaccine 45 pregnancy 90 primaquine 113 prisoners 106 prophylaxis/prevention 79, 94, 100, 106, 108, 114 propolis 37 Prosorba column 75 PWA coalitions 117 pyrimethamine (Daraprim) 79, 104, 108, 114
radiation therapy 73, 93, 110 research priorities & policy 60, 62, 67, 77, 78, 81, 85, 104, 105, 110, 112, 116 R-HEV test 85 rifabutin (Ansamycin) 53, 79, 109 rifampin 79, 102 roxithromycin 75, 81, 95
Salk vaccine (HIV) 98 scabies 98 SCH 39304 99 Septra (co-trimoxazole, TMP-SMX) 79, 108, 114 shiitake 19 somatostatin (Sandostatin) 58, 95 spiramycin 49, 79, 95, 107 steroids 114, 115 sulfadiazine 79, 93, 104, 108 sulfolipids (blue-green algae) 87, 99 sunlight 58
Tagamet (cimetidine) 80 thrush (candidiasis) 37, 96 TIBO derivatives 97 TI-23 108 TLC G-65 109 toltrazuril (Baycox) 111 toxoplasmosis 79, 104, 108, 109, 113 transfer factor 47 treatment access 83, 84, 85, 115, 116 treatment strategy 83, 100, 111 trifluridine (Viroptic) 115 trimethoprim/sulfamethoxazole 79, 108, 114 trimetrexate/leucovorin 49, 52, 108 tuberculosis 106 tumor necrosis factor 87, 88
valley fever (coccidioidomycosis) 41, 96 vidarabine (Vira-A) 79, 94 vinblastine, vincristine 73 vitamin C 111
wasting syndrome 76, 77, 88 women 65, 90, 111, 112, 115
901221
ATN11705
Copyright © 1990 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org
Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1990. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1990. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .